Literature DB >> 11167759

Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III.

V Deutsch1, M Bitan, Y Friedmann, A Eldor, I Vlodavsky.   

Abstract

Connective tissue-activating peptide III (CTAP III), a CXC chemokine derived from the chemokine precursor platelet basic protein (PBP) by proteolytic cleavage, has been identified in platelets, activated macrophages, neutrophils and T lymphocytes. CTAP III can support stem cell-derived haematopoiesis yet inhibits the proliferation of committed megakaryocyte (MK) progenitors. This investigation was aimed at characterizing CTAP III expression in human MKs and determining it's role in MK differentiation. We report high expression of CTAP III in mature human bone marrow (BM) MKs and megakaryoblast cell lines following differentiation induction with phorbol ester 12-myristate 13-acetate (PMA). Immunostaining with anti-CTAP III antibodies demonstrated its prominent presence in platelet producing zones in the cytoplasm and intense staining around the periphery of the large BM MKs. In cultures of logarithmically growing megakaryoblast cell lines DAMI, CHRF-288 or MEG01, which contain primarily 2N cells, only 15% of the cells expressed CTAP III. The addition of PMA stimulated high levels of CTAP III after 24 h in more than 75% of the cells, being expressed in both the 2N and large polyploid MKs. Reverse transcription polymerase chain reaction (RT-PCR) revealed upregulation of CTAP III mRNA after only 1 h of exposure to PMA that was sustained for 24 h. In the bone marrow of idiopathic thrombocytopenic pupura (ITP) patients undergoing accelerated MK maturation and thrombopoiesis, 99% of large MKs and 95% of small MKs expressed high levels of CTAP III. While the biological function of this chemokine in MKs is not known, these studies demonstrate that molecular upregulation of CTAP III in MKs is associated with maturation and, as with other chemokines, may be involved in proliferation arrest and cellular interactions with extracellular matrix and platelet production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11167759     DOI: 10.1046/j.1365-2141.2000.02476.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

2.  Is There a Relationship Between CXCR4 Gene Expression and Prognosis of Immune Thrombocytopenia in Children?

Authors:  Sajedeh Saeidi; Javad Mohammadi-Asl; Mohammad Ali Jalali Far; Ali Amin Asnafi; Firouzeh Dehuri; Yousef Tavakolifar; Najmaldin Saki
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-22       Impact factor: 0.900

3.  Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2.

Authors:  Tommaso Pippucci; Anna Savoia; Silverio Perrotta; Núria Pujol-Moix; Patrizia Noris; Giovanni Castegnaro; Alessandro Pecci; Chiara Gnan; Francesca Punzo; Caterina Marconi; Samuele Gherardi; Giuseppe Loffredo; Daniela De Rocco; Saverio Scianguetta; Serena Barozzi; Pamela Magini; Valeria Bozzi; Luca Dezzani; Mariateresa Di Stazio; Marcella Ferraro; Giovanni Perini; Marco Seri; Carlo L Balduini
Journal:  Am J Hum Genet       Date:  2011-01-07       Impact factor: 11.025

Review 4.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.